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Aim: The aim of this study was to identify genes that are differentially expressed in gastric tumors and to analyze the association of their 
expression level with tumor clinicopathologic features. Methods: In the present research, we used bioinformatic-driven search to iden-
tify miRNA that are down-regulated in gastric tumors and to find their potential targets. Then, the expression levels of some of the 
target mRNAs were investigated using reverse transcription polymerase chain reaction (RT-PCR) analysis. Results: As a result of the 
bioinformatics analysis, fifteen genes were found to be potentially differentially expressed between the tumors and normal gastric tis-
sue. Five of them were chosen for the further analysis (WNT4, FGF12, EFEMP1, CTGF, and HSPG2) due to their important role 
in cell proliferation and differentiation. Expression levels of these genes were evaluated in our collection of frozen tissue samples 
of gastric tumor and paired normal stomach epithelia. Increased FGF12 expression was observed in diffuse type of gastric cancer while 
WNT4 mRNA was found to be down-regulated in intestinal type of gastric cancer. Besides, CTGF gene overexpression was revealed 
in diffuse type of stomach cancer in comparison with that in intestinal type. Up-regulation of CTGF was also associated with lymph 
node metastasis. Conclusions: The findings show its expedient to perform further investigations in order to clarify diagnostic and 
prognostic value of CTGF, FGF12, and WNT4’s in stomach cancer as well as the role of these genes in carcinogenesis.
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Gastric cancer is one of the most common cancers 
worldwide and one of the leading cause for cancer-re-
lated deaths. Incidence rate of gastric cancer in Russia 
was 17.2/100 000 in 2009 ranking second among men 
and third among women. Gastric cancer is also charac-
terized with high one-year mortality rates (53.2%), and 
low overall 5-year relative survival regardless of gender 
(20.2–21.1%.) [1]. Overall prognosis of gastric cancer 
is generally poor due to late manifestation of the di-
sease. On the other hand, the decline in cancer mortality 
trends is related not only to improvement of treatment 
methods but also to early manifestation and accurate 
prognosis of given disease for treatment optimization. 
If gastric cancer is detected at an early stage, the 5-year 
survival rate is approximately 69.3–75.5%. In contrast, 
the 5-year survival rate of patients with advanced-stage 
of the tumor is only 5.1–6.4% [2]. 
In the early stages of gastric cancer, most patients 
are asymptomatic, making it difficult to control the ma-
lignancy rate through early diagnosis and motivational 
therapy. Although there are several diagnostic tools for 
detecting the clinically divergent conditions of gastric 
carcinomas, such as computed tomography, scanning, 
endoscopic ultrasound (EUS), magnetic resonance 
imaging (MRI), and positron emission tomography 
(PET) scans, they are no effective in early diagnosis 
and adequate prognosis of gastric cancer. There are 
practically no reliable methods for early gastric cancer 
diagnosis based on molecular markers detection. The 
most promising variants of biological molecules that 
are already used for that purpose are CA-19.9 (cancer 
antigen 19.9), СА 72-4, and CEA (carcinoembryonic 
antigen). All these markers have a moderate prognostic 
value for approximately one third of patients and also 
have significant cross-reactivity and thus don’t ef-
fective enough for early diagnosis [3]. In the past few 
years some evidences have been obtained illustrating 
potential diagnostic value of a number of secreted pro-
teins such as NF2, NEK6, INHBA, CDH17, and PDCD6. 
However further investigations are needed to confirm 
their clinical value [4, 5]. 
Adenocarcinoma accounts for over 95% of all malig-
nant gastric neoplasms, and generally the term gastric 
cancer refers to adenocarcinoma of the stomach. They 
can be classified based on histopathological features. 
The most commonly used classifications of gastric can-
cer are the World Health Organization (WHO) [6] and the 
Laurén classification. Laurén classification describes 
two main histological types, diffuse and intestinal, 
having different clinicopathological characteristics that 
affect disease prognosis and outcome [7, 8]. Although 
most of the genetic alterations that have been reported 
are observed in both intestinal and diffuse types 
of tumors, it is considered that molecular pathogenesis 
of diffuse and intestinal types of gastric cancer differs 
significantly [9]. It is thought that knowledge of these 
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subtypes of gastric carcinomas due to identification 
and investigation of their genetic differences may be-
come the key step to make the diagnosis and treatment 
of gastric cancer more effective.
Although the most cases of gastric cancer are 
seemed to be sporadic two hereditary syndromes 
have been characterized — hereditary diffuse gastric 
cancer (HDGC) and gastric adenocarcinoma and 
proximal poly posis of the stomach (GAPPS) [10]. HDGC 
syndrome is often attributed to disorders in the work 
of E-cadherin gene (CDH1, cadherin 1, type 1, the major 
regulator of cell adhesion) as a consequence of the 
gene mutations or promoter hypermethylation. Spo-
radic malignant diffuse gastric neoplasms, in turn, are 
associated with functional disorders of following genes: 
RUNX3, CDH1 FGFR2/KSAM, and CDKN2A [11–13]. 
GAPPS is a unique gastric polyposis syndrome 
with a significant risk of gastric adenocarcinoma with 
areas of dysplasia or intestinal type of gastric cancer. 
Mutations in APC, MUTYH, CDH1, SMAD4, BMPR1A, 
STK11, and PTEN genes were studied in several fami-
lies by sequencing of the genes exons and their dele-
tions and duplications assays but causal genetic defect 
remains unidentified [10]. Typical genetic alterations 
of sporadic intestinal gastric carcinomas are inactiva-
tion of HMLH1 gene and mutation of CDX2 (сaudal 
type homeobox transcription factor 2) as well as ps2, 
RARB, HER-2/neu, etc. CDX2 is a transcription factor 
which is involved in epithelium differentiation of colon, 
pancreas and gallbladder. It interacts with such tu-
mor suppressors as APC, E-cadherin as well as with 
bcl-2 (transcription regulator of such colon epithelium 
differentiation factors genes as MUC2, MUC5AC, 
MUC6, and CDX2). The loss of CDX2 expression in the 
case of intestinal type of gastric cancer may be the 
marker of tumor progression [11–13].
In order to find novel molecular markers, transcrip-
tion and proteomic approaches are used. The major goal 
of transcriptional investigations is to identify miRNAs 
mostly expressed in tumors but not in normal tissues. 
It is reached through the analysis of databases con-
taining microarray gene expression data for thousands 
of genes, and through the use of commercial microar-
rays for estimating gene expression level in own col-
lection of normal and tumor tissue specimens [14, 15]. 
The study of proteins expression level by means 
of comparative analysis of the proteome of normal and 
tumor tissue with 2D electrophoresis followed by the 
identification of differently expressed proteins with 
mass spectrometry is also productive enough. The 
confirmation of differences in gene expression is held 
with the use of RT-PCR and WB-analysis of tumor and 
paired normal tissue samples in that case [4, 15–17].
The aim of this study was to reveal the potential bio-
logical markers of different histological types of gastric 
cancer by means of the bioinformatics-driven search 
for cancer-related miRNA and comparative gene 
expression analysis of their targets. The expression 
analysis was performed in paired specimens of normal 
and tumor tissue. During the bioinformatics search 
with miRNA expression databases, not only transcrip-
tional level of candidate genes but also their miRNA 
regulation was estimated. All these greatly improve 
the reliability of the method and restrict the number 
of identified genes taken for further analysis.
MATERIALS AND METHODS
Clinical specimens. This study was approved 
by the Institutional Ethics Committee of Tomsk Cancer 
Research Institute. Informed consents were obtained 
from all patients prior to analysis. Gastric adeno-
carcinoma and paired normal tissue samples were 
obtained from 37 patients who underwent surgical 
resections at the Department of Abdominal and Tho-
racic Oncology of Tomsk  Cancer Research Institute 
of Siberian Branch of Russian Academy of Science 
(Tomsk, Russia). Surgical pathologic staging was 
assigned according to the TNM Classification [18]. 
A summary of clinicopathologic information for all 
patients is shown in Table 1. 
Table 1. Clinicopathologic features of all patients (n=37)
Clinicopathological parameter N (%)
Depth of invasion T1 3 (8.11)
T2 15 (40.54)
T3 10 (27.03)
T4 9 (24.32)
Nodal status N0 14 (37.83)
N1 16 (43.24)
N2 6 (16.22)
N3 1 (2.70)
Metastasis M0 33 (91.7)
M1 3 (8.3)
Age ≤ 50 8 (21.62)
> 50 29 (78.38)
Histological type diffuse 16 (43.24)
intestnal 21 (56.76)
Stage I 10 (27.78)
II 7 (19.44)
III 11 (30.56)
IV 8 (22.22)
Gender male 21 (55.56)
female 16 (44.44)
Degree of differenti-
ation
G1 1 (3.1)
G2 14 (43.75)
G3 17 (53.15)
Notes: TNM classification: T — the extent of the primary tumor; N — the ab-
sence or presence and extent of regional lymph node metastasis; M — the 
absence or presence of distant metastasis. 
RNA isolation and cDNA synthesis. Tissue 
samples were obtained from patients during op-
eration, kept in “RNAlater” solution (“Ambion”, USA) 
at temperature of +4°C overnight and then stored at 
−80°C. These samples were homogenized with Sarto-
rius Mikro Dismembrator U (“Eppendorf”, Germany) 
at 7300 rpm under cooling with liquid nitrogen. The 
RNA was extracted from the tissue samples using the 
RNeasy mini kit plus DNase I digestion (Qiagen, Gmbh, 
Hilden; Cat no: 74106) as per the manufacturer’s in-
structions. RNA was reverse transcribed into cDNA 
using the RevertAid kit with random hexanucleotide 
primers (“Fermentas”, Lithuania) following the manu-
facturer’s instructions.
RNA quality determination. RNA concentration 
and quality were measured with a NanoDrop-2000 spec-
trophotometer (“Thermo Scientific”, USA). The con-
centration of RNA ranged from 80 to 250 ng/μl. The 
optical density ratios at 260/280 and 260/230 to ex-
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amine RNA quality were in the range of 1.95–2.05 and 
1.90–2.31, respectively. RNA integrity was assessed 
by visualization of the 28S and 18S ribosomal RNA 
in 1.5% agarose gels followed by 0.02% ethidium 
bromide staining. RNA was stored at −80°C for further 
use. In order to estimate genomic DNA contamina-
tion of extracted RNA no template control (NTC) was 
performed. The control RT reactions contained all 
components including template RNA, except for the 
reverse transcriptase. 
Quantitative real time PCR. Validation of t he gene 
expression was done using comparative Cq method 
of quantitative real time RT-PCR. ACTB was chosen for 
normalizing the data [8]. Each reaction was performed 
in a total volume of 15 μl.
qRT-PCR was performed in triplicate reactions 
in a volume of 15 μl containing 250 lM dNTPs (“Siben-
zyme”, Russia), 300 μM forward and reverse primers, 
200 μM probe, 2.5 mM Mgastric cancerl2, 19 SE buffer 
(67 mM Tris–HCl pH 8.8 at 25 °C, 16.6 mM (NH4)2SO4, 
0.01% Tween-20), 2.5U Hot Start Taq polymerase (“Si-
benzyme”, Russia), and 50 ng of template cDNA. Sam-
ples were heated for 10 min at 95 °C, followed by 40 cy-
cles of amplification for 10 s at 95 °C and 27 s at 60 °C.
Primer and probes were designed using Vec-
tor NTI 11.5 and NCBI Nucleotide Database 
(http://www.ncbi.nlm.nih.gov/genbank/) (Table 2).
Table 2. Sequence of the primers and probes used in the study
Gene GenBank Acces-sion Sequence
De-
sign
ACTB (actin 
beta)
NM_001101.3
75 bp
F
R
Probe
5’-gagaagatgacccagat-
catgtt-3’
5’-atagcacagcctggatag-
caa-3’
 FAM 5’-agaccttcaa-
caccccagccat-3’BHQ1
OrD
CTGF (con-
nective tissue 
growth factor)
NM_001901.2
78 bp
F
R
Probe
5’-gtgtgcaccgccaaa-
gat-3’
5’-gctgctctg-
gaaggactctc-3’
FAM 5’-tgctccctg-
catcttcggtgg-3’BHQ1
OrD
EFEMP1 (EGF 
containing fib-
ulin-like extra-
cellular matrix 
protein 1)
NM_001039348.2
102 bp
F
R
Probe
5’- agtcacaggacacc-
gaagaa-3’
5’-gtcacattcat-
caatatctttgca-3’
FAM 5’-tgcactgacg-
gatatgagtggga-3’BHQ1
OrD
FGF12 (fibro-
blast growth 
factor 12)
NM_004113.5
77 bp
F
R
Probe
5’-cgaaaacagcgacta-
cactct-3’
5’-tagccttcactccttg-
gatgg-3’
FAM 5’-ccgtgggcctgc-
gtgtagt-3’BHQ1
OrD
HSPG2 per-
lecan (heparan 
sulfate proteo-
glycan 2)
NM_005529.5
137 bp
F
R
Probe
5’-cctgccaggactgt-
gcc-3’
5’-gttgtgctggcattgc-
ga-3’
FAM 5’-cagacctgtgc-
cacccagagact-3’BHQ1
OrD
WNT-4 (wing-
less-type 
MMTV integra-
tion site fami-
ly, member 4)
NM_030761.4
76 bp
F
R
Probe
5’-cgagcaactggctg-
tacct-3’
5’-ttgagtttctcgcac-
gtctc-3’
FAM 5’-cgtcggtggggag-
catctca-3’BHQ1
OrD
Notes :  M number  accord ing to  NCBI  Nucleot ide Database 
(http://www.ncbi.nlm.nih.gov/nuccore); F — forward primer; R — reverse 
primer; OrD — Original design.
Bioinformatics analysis. Bioinformatics analysis 
using databases and analysis of literature sources 
was performed for detection of miRNA with signifi-
cant down-regulation in tumor tissue. To identify the 
most probable targeted mRNAs the original algo-
rithm of TargetScan (http://www.targetscan.org.) 
and SAGE (http://cgap.nci.nih.gov/SAGE) data 
analysis was performed [19]. The search for up-
regulated tumor-associated mRNAs was carried out 
with the usage of following informational resources: 
Oncomine (https://www.oncomine.com/), dbEST 
(http://www.ncbi.nlm.nih.gov/dbEST/), SAGE and 
Chen sample collection [20].
Statistical analysis. Mann — Whitney U-test 
was used to assay the significance of the differences 
obtained. The median and range for the expression 
value of each gene in each group were calculated 
using Statistica 8.0 software (ver. 6.1, serial number 
1203d, StatSoft, Inc.). A single gene was defined 
as overexpressed when more than twofold expression 
increase was observed during the analysis in a tumor 
tissue sample versus its paired normal. The signifi-
cance of these differences was evaluated using the 
Chi-square test. Two-tailed test and Yates’ chi-squared 
test were used for obtaining the p value in the case 
of small groups (less than 5) being analyzed.
RESULTS AND DISCUSSION
miRNAs are small single-stranded regulatory 
RNAs capable of interfering with mRNAs and thus are 
important element of post-transcriptional gene silenc-
ing mechanism. There are approximately 700 miRNAs 
in humans and up to one third of human total mRNA 
are potential miRNA targets. It is believed that differ-
ent miRNAs can be involved in carcinogenesis playing 
oncogenic as well as tumor suppressor role [21]. De-
termination of miRNA expression pattern can be used 
for identification of potential protein tumor markers 
[22]. For it to be effective a number of significantly 
down-regulated miRNA as well their targets should 
be found in tumor. Here one faced with two important 
circumstances. The first of them is a possibility that 
a single mRNA could be targeted by several different 
miRNA providing different regulating influence on the 
gene expression. The second is the requirement 
to consider the targeted both mRNA transcription pro-
file and its translation activity in tumor. These problems 
were solved using our approach of the double selection 
method testing the transcriptional as well as transla-
tional levels of genes under study [18]. The influence 
of both up and down-regulated miRNA in tumors was 
also estimated.
At the first stage of bioinformatics-driven search, 
approximately one hundred of literature sources were 
analyzed. As a result, 90 miRNA were found to be dif-
ferentially expressed in tumor compared to normal 
tissue according to literature data. 50 of them were 
found to be significantly down-regulated in tu-
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mor, whereas the others were up-regulated. Then, 
mRNA targets prediction with the use of TargetScan 
(http://www.targetscan.org.) database as well as the 
choice of more perspective mRNA-miRNA pairs were 
carried out. During the procedure each of these pairs 
were assigned to the ε number (score in TargetScan) 
showing the accuracy of the prediction as well as the 
miRNA influence on its targeted mRNA translation. 
As a result a list was obtained containing miRNA ca-
pable to regulate 15 998 genes of the whole human 
genome. Then 935 of genes coding secreted pro-
teins were chosen for further work. 100 of them were 
predicted as the most perspective using the value 
of scoring-function S (that reflects the probability for 
protein translation to be increased). Genes with the 
highest S were considered to be the most promising. 
S = Σ εi– – 2 Σ εi+
εi+ and εi– are the ε value from TargetScan data-
base for up- and down-regulated miRNAs in tumors 
respectively. 2 — coefficient reflecting the strictness 
of used criteria.
To identify the number of clones in clone libra-
ries of normal and tumor tissue, GeneHub GEPIS 
web resource of dbEST (Gene Expression Profil-
ing In Silico, http://research-public.gene.com/ 
Research/genentech/genehub-gepis/index.html.) 
was used. The expected changes in the transcriptional 
level of identified genes were estimated with Oncomine 
database (www.oncomine.org) based on the microar-
ray investigations.
Identif icat ion of  proteins that could en-
ter the bloodstream using Babelomics web-ser-
vice (http://babelomics.bioinfo.cipf.es/) was 
the next stage of our research. The additional 
check was held with the GeneCards database 
(http://genecards.org). The further screening for 
biological markers was carried out with Oncomine, 
dbEST (http://www.ncbi.nlm.nih.gov/dbEST/) and 
SAGE (http://cgap.nci.nih.gov/SAGE) databases. 
The genes under investigation were selected for 
further analysis when the information  about their 
overexpression (two-fold increase or higher) in gastric 
tumors was received at least from two of mentioned 
databases. This search resulted in sixteen gene list 
аs final candidates because the increase of both 
their transcriptional and translational levels in tumors 
was probable. To validate differential gene expres-
sion in stomach cancer specimens versus normal 
tissue with RT-PCR analysis we selected five genes 
(WNT4, FGF12, EFEMP1, CTGF, and HSPG2) that are 
considered to contribute to carcinogenesis regulating 
cell proliferation, differentiation, division, migration, 
apoptosis, gene expression and regeneration.
It is important that some of these genes are func-
tionally linked to each other through the key tran-
scriptional cancer-related factor, TGFβ (transforming 
growth factor beta) and regulatory glycoprotein HSPG 
(heparan-sulfate proteoglycan), that are responsible 
for epithelial-mesenchymal transition (EMT), as a prin-
cipal step for tumor dissemination. 
The expression analysis of WNT4, FGF12, EFEMP1, 
CTGF, and HSPG2 genes was done using quantitative 
RT-PCR in the own collection of frozen tumor and 
paired normal samples collected from patients treated 
in Tomsk Cancer Institute.
No significant differences were found in the expres-
sion levels of genes to be tested when the analysis 
was done for the total group of patients. There was 
also no significant association between WNT4, FGF12, 
EFEMP1, CTGF, and HSPG2 gene expression level and 
tumor differentiation status, stage, metastasis, as well 
as age and gender of patients (p > 0.05, data not 
shown). However, the individual analysis showed more 
than two-fold FGF12 expression increase in tumor 
tissue versus normal gastric mucosa among 42.5% 
of patients (р = 0.01, Yates’ chi-squared test, Table 3).
Table 3. WNT4, HSPG2, CTGF, EFEMP1and FGF12 gene expression alte-
rations in gastric tumor tissue and paired normal specimens
Genes Increased expressionn (%)
Decreased expression
n (%)
Equal expression
n (%)
WNT4 8 (20) 13 (32,5) 19 (47,5)
HSPG2 5 (12,5) 6 (15) 29 (72,5)
CTGF 12 (30) 7 (17,5) 21 (52,5)
EFEMP1 10 (25) 11 (27,5) 19 (47,5)
FGF12 17 (42,5) 11 (27,5) 12 (30)
Increased expression of CTGF gene in the tu-
mor compared with normal tissue was observed 
in patients with metastases in regional lymph nodes 
(0.0625 (0.0510; 0.1090) versus 0.0463 (0.0250; 
0.0883), p = 0.042, median (range), Mann — Whitney 
U-test). No differences in CTGF gene expression were 
found in patients with local tumor growth.
When patients were stratified by tumor histological 
type, the increased FGF12 expression was found in dif-
fuse type of stomach cancer in comparison with nor-
mal tissue (p=0.049, Mann —  Whitney U-test, Table 4), 
the increase in FGF12 gene expression level in tumors 
was observed in 62,5% of patients, while there was 
no differential FGF12 expression in intestinal type 
of tumors. These findings suggest the FGF12 invol-
ving in pathogenesis of diffuse type of gastric cancer.
The significant down-regulation of WNT4 gene was 
found in intestinal type of tumors versus normal mu-
cosa (Table 5). Two-fold expression decrease was ob-
served in 47.6% of patients, while gene up-regulation 
was noted only in one person (4.8%).
The CTGF gene expression was significantly higher 
in patients with diffuse type of stomach cancer than 
in patients with intestinal type (р = 0.012; Tables 4, 5), 
Mann — Whitney U-test).
Thus, the analysis of gene expression revealed 
a significant difference in only three genes (FGF12, 
WNT4, and CTGF) between the tumor of different 
histological types and normal tissue. FGF12 gene 
showed differential expression in diffuse type of cancer 
samples for more than 60% of patients. All members 
of FGF family are known to play an important role in em-
bryogenesis, morphogenesis and regeneration as well 
as cell mitosis, survival and proliferation [23]. Although 
the specific function of FGF12 is still to be studied, 
evidence exists that it contains clusters of basic resi-
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dues that have been demonstrated to act as a nuclear 
localization signal. When transfected into mammalian 
cells, FGF12 was accumulated in the nucleus, but was 
not secreted [24]. On the other hand, it participates 
in tissue regulation through internalization into cells 
interacting with its cell-penetrating domen (CPP) [24]. 
There are although indirect evidences of FGF12 in-
volvement in angiogenesis [25] as well as inhibition 
of apoptosis suggesting its potential oncogenic role 
[26]. However, participation of FGF12 in diffuse type 
of gastric cancer pathogenesis suggested in our re-
search requires clarification. 
Table 4. WNT4, HSPG2, CTGF, EFEMP1 and FGF12 gene expression level 
in diffuse type of gastric tumors and paired normal mucosa
Genes Diffuse gastric cancerMe (Q25–75)
Normal tissue
Me (Q25–75) p
WNT4 0.0520
(0.0135; 0.0762)
0.0314
(0.0131; 0.0639)
0.373
HSPG2 0.1091
(0.0715; 0.2693)
0.1317
(0.0931; 0.1872)
0.756
CTGF 0.0932
(0.0586; 0.1492)
0.0744
(0.0364; 0.1333)
0.33 (0.012*)
EFEMP1 0.0556
(0.0403; 0.1057)
0.0415
(0.0309; 0.0747)
0.093
FGF12 0.0015
(0.0010; 0.0024)
0.0009
(0.0002; 0.0019)
0.042
Notes: Me — median; Q25–75 — range; p — Mann — Whitney U-test; *p-va-
lue obtained for the groups “diffuse” and “intestinal” (Table 5).
Table 5. WNT4, HSPG2, CTGF, EFEMP1 and FGF12 gene expression level 
in intestinal type of gastric tumors and paired normal mucosa
Genes Intestinal gastric cancerMe (Q25–75)
Normal tissue
Me (Q25–75) p
WNT4 0.0182
(0.0069; 0.0557)
0.0505
(0.0236; 0.1109)
0.048
HSPG2 0.1141
(0.0741; 0.1935)
0.1496
(0.0879; 0.2032)
0.291
CTGF 0.0482
(0.0274; 0.0636)
0.0581
(0.0296; 0.0831)
0.402
EFEMP1 0.0338
(0.0168; 0.0826)
0.0458
(0.0247; 0.1080)
0.130
FGF12 0.0007
(0.0004; 0.0020)
0.0009
(0.0006; 0.0014)
0.705
Notes: Me — median; Q25–75 — range; p — Mann — Whitney U-test. 
CTGF gene was found to be overexpressed 
in diffuse type of tumor versus intestinal one as well 
as in tumors with lymph node metastasis that is thought 
to point its contribution to cancer progression. CTGF 
was discovered in 90-s as growth factor secreted 
by human endothelial cells [27]. It takes part in regula-
tion of cell proliferation, migration, survival, adhesion 
as well as angiogenesis and therefore could be in-
volved in carcinogenesis [28, 29]. Indeed a functional 
relationship between CTGF and TGFβ as well as their 
involvement into EMT, which is considered as one 
of the major mechanisms providing tumor metastatic 
potential have been reported earlier. The process 
of intracellular signal transduction from receptors into 
the nucleus downstream of TGF superfamily ligands 
is rather conserved and acts through SMAD proteins 
activation [30]. TGFβ as the key player in EMT regu-
lates CTGF expression by means of gastric cancer-rich 
response element in the CTGF promoter and thereby 
Smad1-dependent increased promoter activity [31]. 
The CTGF gene product inhibits E-cadherin expression 
that is similar to the major way of TGFβ-dependent EMT 
[32]. It is also known that E-cadherin gene down-regu-
lation is one of the molecular mechanisms of hereditary 
diffuse histotype of gastric cancer development. Thus 
it can be assumed that data received about increased 
CTGF gene expression reflect its role in gastric cancer 
diffuse type pathogenesis.
There is a lot of information about CTGF involve-
ment in pathogenesis of different malignant tumors 
(breast cancer, pancreatic cancer, ovarian cancer, 
glioblastomas etc.) [33]. According to some authors 
CTGF high mRNA level has prognostic value in sto-
mach cancer and associated with metastasis and low 
survival rates that are in agreement with our finding 
[34]. In addition it is thought to contribute to tumor 
drug resistance [33]. 
As for WNT4 gene expression level, we observed 
differential expression (namely its decrease in intestinal 
gastric tumors versus normal tissue with more than two-
fold reduction) in half of the patients. WNT4 is a member 
of gene family encoding secreted signal proteins regu-
lated cell differentiation that supposes its participation 
in carcinogenesis. Normally WNT4 regulates breast 
stem cells proliferation in response to progesterone 
and also plays an important role in embryogenesis [35].
WNT genes up-regulation was found in gastric 
cancer, leukemia and some other malignances [4, 
35, 36]. As for WNT gene family contribution to tumor 
pathogenesis WNT/beta-catenin pathway is thought 
to be crucial. Beta-catenin regulates expression 
of such oncogenes as c-MYC and cyclin D1 and 
participates in cell adhesion through interaction with 
cadherin. Activation of this pathway by H. pylori infec-
tion is critical event prior malignancy. WNT proteins 
promote beta-catenin gene expression contributing 
to malignancy although this event could be related not 
only to WNT genes activation but with up-regulation 
of WNT receptors genes and RAC1 gene [37, 38]
In order to clarify the fact of WNT down regula-
tion in intestinal type of gastric cancer in our study, 
we analyzed whether WNT4 gene expression alteration 
is associated with H. pylori infection in gastric cancer 
patients but did not observed any association. It re-
mains an open question what could be the possible 
reason of WNT4 down-regulation in intestinal type 
of gastric tumors.
The data obtained suggest the importance of fur-
ther investigations in order to make clear the role 
of WNT4, FGF12, and CTGF genes in pathogenesis 
of different types of gastric cancer as well as their 
diagnostic and prognostic value.
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